A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Oct 28

PMID 37895923

Authors

Claudio Festuccia

Miriam Corrado

Alessandra Rossetti

Riccardo Castelli

Alessio Lodola

Giovanni Luca Gravina

Massimiliano Tognolini

Carmine Giorgio

Affiliations

Soon will be listed here.

Abstract

The Eph kinases are the largest receptor tyrosine kinases (RTKs) family in humans. PC3 human prostate adenocarcinoma cells are a well-established model for studying Eph-ephrin pharmacology as they naturally express a high level of EphA2, a promising target for new cancer therapies. A pharmacological approach with agonists did not show significant efficacy on tumor growth in prostate orthotopic murine models, but reduced distal metastasis formation. In order to improve the comprehension of the pharmacological targeting of Eph receptors in prostate cancer, in the present work, we investigated the efficacy of Eph antagonism both in vitro and in vivo, using UniPR1331, a small orally bioavailable Eph-ephrin interaction inhibitor. UniPR1331 was able to inhibit PC3 cells' growth in vitro in a dose-dependent manner, affecting the cell cycle and inducing apoptosis. Moreover, UniPR1331 promoted the PC3 epithelial phenotype, downregulating epithelial mesenchymal transition (EMT) markers. As a consequence, UniPR1331 reduced in vitro PC3 migration, invasion, and vasculomimicry capabilities. The antitumor activity of UniPR1331 was confirmed in vivo when administered alone or in combination with cytotoxic drugs in PC3-xenograft mice. Our results demonstrated that Eph antagonism is a promising strategy for inhibiting prostate cancer growth, especially in combination with cytotoxic drugs.

Citing Articles

EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities.

Toracchio L, Carrabotta M, Mancarella C, Morrione A, Scotlandi K Int J Mol Sci. 2024; 25(22).

PMID: 39596256 PMC: 11594831. DOI: 10.3390/ijms252212191.

References

Fox B, Tabone C, Kandpal R . Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun. 2006; 342(4):1263-72. DOI: 10.1016/j.bbrc.2006.02.099. View

Konstantinova I, Nikolova G, Ohara-Imaizumi M, Meda P, Kucera T, Zarbalis K . EphA-Ephrin-A-mediated beta cell communication regulates insulin secretion from pancreatic islets. Cell. 2007; 129(2):359-70. DOI: 10.1016/j.cell.2007.02.044. View

Arora S, Scott A, Janes P . Eph Receptors in Cancer. Biomedicines. 2023; 11(2). PMC: 9953285. DOI: 10.3390/biomedicines11020315. View

Giorgio C, Hassan Mohamed I, Flammini L, Barocelli E, Incerti M, Lodola A . Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PLoS One. 2011; 6(3):e18128. PMC: 3068151. DOI: 10.1371/journal.pone.0018128. View

Troster A, Jores N, Mineev K, Sreeramulu S, DiPrima M, Tosato G . Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer. ChemMedChem. 2023; 18(23):e202300420. PMC: 10843416. DOI: 10.1002/cmdc.202300420. View

Serttas R, Erdogan S . Pretreatment of prostate cancer cells with salinomycin and Wnt inhibitor increases the efficacy of cabazitaxel by inducing apoptosis and decreasing cancer stem cells. Med Oncol. 2023; 40(7):194. DOI: 10.1007/s12032-023-02062-1. View

Janes P, Vail M, Ernst M, Scott A . Eph Receptors in the Immunosuppressive Tumor Microenvironment. Cancer Res. 2020; 81(4):801-805. DOI: 10.1158/0008-5472.CAN-20-3047. View

Giorgio C, Zanotti I, Lodola A, Tognolini M . Ephrin or not? Six tough questions on Eph targeting. Expert Opin Ther Targets. 2020; 24(5):403-415. DOI: 10.1080/14728222.2020.1745187. View

Lin J, Tsai T, Liao P, Lin Y, Lin Y, Chen H . Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling. Carcinogenesis. 2012; 34(2):406-14. DOI: 10.1093/carcin/bgs359. View

10.

Buckens O, Hassouni B, Giovannetti E, Peters G . The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment. Expert Opin Investig Drugs. 2020; 29(6):567-582. DOI: 10.1080/13543784.2020.1762566. View

11.

Tae J, Chang I . Animal models of bone metastatic prostate cancer. Investig Clin Urol. 2023; 64(3):219-228. PMC: 10172043. DOI: 10.4111/icu.20230026. View

12.

Shukla S, Gupta S . Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle. 2007; 6(9):1102-14. DOI: 10.4161/cc.6.9.4146. View

13.

Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop G . A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One. 2012; 7(8):e42120. PMC: 3419725. DOI: 10.1371/journal.pone.0042120. View

14.

Kim S, Kim K, Yu S, Park S, Choi H, Ji J . Autophagy inhibition enhances silibinin-induced apoptosis by regulating reactive oxygen species production in human prostate cancer PC-3 cells. Biochem Biophys Res Commun. 2015; 468(1-2):151-6. DOI: 10.1016/j.bbrc.2015.10.143. View

15.

Ferreira J, Peixoto A, Neves M, Gaiteiro C, Reis C, Assaraf Y . Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resist Updat. 2016; 24:34-54. DOI: 10.1016/j.drup.2015.11.003. View

16.

Nomura T, Goritz C, Catchpole T, Henkemeyer M, Frisen J . EphB signaling controls lineage plasticity of adult neural stem cell niche cells. Cell Stem Cell. 2010; 7(6):730-43. PMC: 3003830. DOI: 10.1016/j.stem.2010.11.009. View

17.

Tognolini M, Incerti M, Pala D, Russo S, Castelli R, Hassan-Mohamed I . Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists. ChemMedChem. 2013; 9(1):67-72. DOI: 10.1002/cmdc.201300305. View

18.

Ferrari F, Giorgio C, Zappia A, Ballabeni V, Bertoni S, Barocelli E . Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach. Biochem Pharmacol. 2023; 209:115452. DOI: 10.1016/j.bcp.2023.115452. View

19.

Kania A, Klein R . Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol. 2016; 17(4):240-56. DOI: 10.1038/nrm.2015.16. View

20.

Yang M, Liu H, Qiu G, Gao F . Silencing Akt1 enhances the resistance of prostate cancer cells to starvation and inhibits starvation-induced lung metastasis through epithelial-mesenchymal transition in prostate cancer. Med Oncol. 2021; 39(1):8. DOI: 10.1007/s12032-021-01600-z. View